Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Next Previous
Trial Profile

A multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ADHERE; CHARM
  • Sponsors Abbott Laboratories

Most Recent Events

  • 07 Mar 2018 Results of pooled data from 11 induction, maintenance and open-label extension studies of adalimumab, were published in the Advances in Therapy.
  • 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
  • 07 Nov 2016 Results of post hoc analysis of this and other five studies (CLASSIC-I, GAIN, CHARM, EXTEND, ULTRA 1 AND ULTRA 2) published in the Alimentary Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top